Background: A number of studies have demonstrated the presence of a diabetic cardiomyopathy, increasing the risk of heart failure development in this population. Improvements in present-day risk factor control may have modified the risk of diabetes-associated cardiomyopathy. Aim: We sought to determine the contemporary impact of diabetes mellitus (DM) on the prevalence of cardiomyopathy in at-risk patients with and without adjustment for risk factor control. Design: A cross-sectional study in a population at risk for heart failure. Methods: Those with diabetes were compared to those with other cardiovascular risk factors, unmatched, matched for age and gender and then matched for age, gender, body mass index, systolic blood pressure and low density lipoprotein cholesterol. Results: In total, 1399 patients enrolled in the St Vincent's Screening to Prevent Heart Failure
(STOP-HF) cohort were included. About 543 participants had an established history of DM. In the whole sample, Stage B heart failure (asymptomatic cardiomyopathy) was not found more frequently among the diabetic cohort compared to those without diabetes [113 (20.8%) vs. 154 (18.0%), P = 0.22], even when matched for age and gender. When controlling for these risk factors and risk factor control Stage B was found to be more prevalent in those with diabetes [88 (22.2%)] compared to those without diabetes [65 (16.4%), P = 0.048]. Conclusion: In this cohort of patients with established risk factors for Stage B heart failure superior risk factor management among the diabetic population appears to dilute the independent diabetic insult to left ventricular structure and function, underlining the importance and benefit of effective risk factor control in this population on cardiovascular outcomes.
Background
Prevention of heart failure remains a major challenge in the Western world as prevalence and costs of this condition remain high and are predicted to increase further. 1 Preventive strategies should focus on at-risk cohorts and in particular on those with evidence of asymptomatic abnormalities of left ventricular structure and/or function, now referred to as Stage B heart failure. The growing epidemic of diabetes 2 and its proven link with incident heart failure 3-5 poses a significant challenge. While the association between diabetes and heart failure is, in part, due to the greater prevalence of cardiovascular risk factors, an independent diabetic-specific cardiomyopathy driven by metabolic abnormalities of this condition has also been described.
While the epidemiological horizon for diabetes and heart failure remains a concern some reassurance may be obtained from the impact of improved risk factor control on cardiovascular events among patients with diabetes over the recent past. However, we have no information of the potential impact of improved risk factor control on features of Stage B heart failure among populations with diabetes. This important issue requires clarification in contemporary clinical practice following several decades of disease management in diabetes with intensive focus on cardiovascular risk.
Thus, the objective of this study was to define the present day prevalence of Stage B heart failure in diabetic patients compared with non-diabetic cohorts and assess the impact of the contemporary approach to risk factor control on this important determinant of cardiovascular risk among diabetics.
Methods

Patient population
This study reports from within the St Vincent s Screening to Prevent Heart Failure (STOP-HF) cohort of patients which has been described in detail elsewhere. 6 This study has been approved by the St Vincents University Hospital Research Ethics Committee. In brief, the STOP-HF cohort is an on-going project actively recruiting individuals aged over 40 years with risk factors for heart failure. These patients are predominantly referred by their primary care physician. All patients undergo screening with B-type natriuretic peptide (BNP). Participants with a BNP level of 50 pg/ml or higher undergo Doppler echocardiography and review by a cardiologist at the study center, who decides on further investigation and management. In addition to disclosure of BNP values to patients and the primary care physicians, the focus of the specialist intervention for those with elevated BNP is multidimensional. This approach includes optimal risk factor management with the most appropriate therapy and complete investigation and treatment of abnormalities defined on examination or on Doppler echocardiography. In addition, all patients receive further coaching by a specialist nurse who emphasizes individual risk status and the importance of adherence to medication and healthy lifestyle behaviors.
To address the specific hypothesis outlined earlier, enrollment over the period 2010-12 focused on recruiting patients with a history of diabetes to supplement those already enrolled to the STOP-HF project. The increased diabetic enrollment was obtained in a non-selective manner from our diabetic services at St Vincent's Healthcare Group. From the view point of the specific hypothesis of this study it is important to note that the STOP-HF project does not enroll patients with a history of heart failure or proven asymptomatic left ventricular systolic dysfunction (LVSD).
To describe the association between diabetes mellitus (DM) and cardiomyopathy, the first available Doppler-echocardiogram performed from 2010 onwards was used along with data obtained at that clinical assessment. The stipulation to use studies during 2010 or beyond was adhered to even among patients enrolled to STOP HF prior to 2010 to reduce any potential impact of changing approaches to the performance or analysis of the ultrasound studies. Standard risk factors for heart failure were noted at these assessments. In addition, all cardiovascular and diabetic medications were noted, and blood samples were taken for BNP, random blood glucose and lipid profile. Metabolic syndrome was defined as three of five of the following features: the presence of a diagnosis of DM or impaired glucose regulation, established medical history/diagnosis of hypertension or use of anti-hypertensive agents, plasma triglycerides !150 mg/dl, high density lipoprotein (HDL) cholesterol <40 mg/dl (men) or <50 mg/dl/l (women) or use of cholesterol-lowering agents (statins), body mass index (BMI) >30 kg/m 2 . 7 Impaired glucose regulation was defined as a random capillary glucose !120 mg/dl. 8 
Doppler echocardiography
Doppler echocardiographic studies were performed by two experienced echocardiographers who were blinded to the diabetes status of the patient. Studies were performed using standard definitions for manifestations of structural and functional impairment of the left ventricle. Left ventricular mass (Devereux formula) was defined as LVM (g) = 0. 
Statistics
All analyses were performed with R software, version 2.7.2 (CRAN Project). Propensity matching used the minimum Mahalanobis distance within propensity score calipers method. 11 All descriptive statistics for continuous variables are reported as median [IQR] . Where data can be assumed to be normally distributed, the median is equal to the mean, and the standard deviation is approximately equal to 0.75 times the IQR. Where P values are reported they refer to chi-square tests of independence if data are categorical/binary, Wilcoxon rank sum tests if data are continuous (but not power transformable to normally distributed values) and independent t-tests if data were power transformable to normally distributed values. All tests are two-tailed with a = 0.05, and normality was tested using the Shapiro-Wilk test with a = 0.05.
For patients with missing echocardiographic data, the following rules were applied. If a patient had one or more of LVDD, LVSD or moderate to severe left ventricular mass index (LVMI), they were classified as having a cardiomyopathy even if they were missing measurements of one of the other parameters. If they had normal measurements of any combination of LVDD, EF and/or LVMI but were missing measurement of one of these parameters they were excluded from the analysis. Analysis was initially performed on the total sample and subsequently on two propensity matched samples. The first (Matched Sample 1) was matched on age and gender, and the second (Matched Sample 2) on age, gender, BMI, systolic blood pressure (SBP) and low density lipoprotein (LDL) cholesterol.
Sample size calculations were based on the prevalence of LVDD. The prevalence of LVDD was assumed to be 39% in the diabetes group and 25.5% in the non-diabetic group. 12 Using a 1:1 allocation ratio of participants with DM and those without DM, a = 0.05 (two-tailed), power = 0.80 and an assumed contribution of 20% variation in LVDD from other variables, the total minimum required sample size was 472 participants (236 DM and 236 non-DM).
Results
This study reports on 1399 patients with an available and interpretable Doppler-echocardiogram from a total available population enrolled in the STOP-HF cohort at the time of this project ( Table 1 , total population). It includes 543 patients with an established history of DM, the remainder non-diabetic with at least one risk factor for ventricular dysfunction. The diabetic cohort were younger, more likely to be male, had a higher BMI and a lower prevalence of hypertension. Several cardiovascular drugs were used more extensively in the diabetes cohort, especially anti-platelet therapy, statins and renin angiotensin aldosterone system (RAAS) modulating therapy.
Several risk factors were under better control in the diabetes cohort with lower LDL cholesterol and lower SBP. HDL was marginally higher in the nondiabetes group.
The demographics of the propensity matched populations ( Table 1 , matched population 1) still demonstrated differences but almost exclusively in the area of prevalence of risk factors and risk factor management.
Prevalence of Stage B heart failure
In the total population, mean LVEF was marginally less in the diabetic cohort, and the prevalence of LVSD was equivalent between the groups. There was no significant difference in the prevalence of LVDD or increased LVMI between the two cohorts. Taken together, the prevalence of cardiomyopathy was observed to a similar extent in both groups.
Controlling for age, gender, the prevalence of LVSD, LVDD and increased LVM remained similar in the two groups. As before, in overall terms, the prevalence of Stage B heart failure was no greater in the diabetic cohort in this analysis.
However, it was evident that significant differences existed between the cohorts in terms of presence of risk factors and risk factor management, which likely impacted on the initial analysis above. Prevalence of hypertension was greater in the non-diabetic cohort, and risk factor management was superior in the diabetic cohort as evidenced by lower SBP and cholesterol levels and more prevalent use of cardio-protective medications. The importance of these issues to the relative prevalence of cardiomyopathy between the two populations is underlined by the demonstration of a higher prevalence of cardiomyopathy in the diabetic cohort when populations are further controlled for factors linked to the effectiveness of risk factor control ( Table 2 , Matched Sample 2, Figure 1 ). features of cardiomyopathy in those with diabetes compared to a temporally matched population with standard cardiovascular risk factors. The results demonstrate no significant difference in the population prevalence of Stage B heart failure in an analysis adjusted for age and gender. However, it was also noted in this analysis that the diabetic cohort had superior risk factor management, in particular lower blood pressure and LDL values and higher use of statins, RAAS modifying therapy and aspirin. Further in a sample matched for age, gender, BMI, SBP and LDL there was a higher prevalence of stage B in those with diabetes. These observations on diabetic cardiomyopathy are in keeping with other studies such as VADT, ACCORD and ADVANCE [13] [14] [15] which have consistently shown that risk factor management appears to be the most effective approach for prevention of cardiac and macrovascular complications in those with diabetes. The link between diabetes and incident heart failure has been clearly demonstrated. Two factors would appear to drive this increased risk; increased prevalence of the routine risk factors for ventricular dysfunction and the specific well-described diabetic cardiomyopathy. The latter is the result of many factors associated with diabetes including metabolic derangements, heightened activity of the sympathetic nervous and RAASs, increased production of oxygen free radicals, mitochondrial dysfunction and autonomic neuropathy. 16, 17 In isolation or in concert, these abnormalities have the capacity to drive cardiomyocyte hypertrophy and dysfunction and abnormalities of the cardiac interstitium and vasculature. Heightened prevalence of increased left ventricular mass and impairment of systolic and diastolic function, manifestations of diabetic cardiomyopathy, likely contribute to the increased risk of heart failure. 18 As outlined earlier cardiovascular risk factor control rather than glycemic control appears to be central to reduction in macrovascular complications of diabetes. A decade ago, the Steno-2 Study demonstrated a significantly lower risk of cardiovascular disease in diabetes patients assigned to an intensified multifactorial intervention resulting in better blood pressure and lipid profiles as well as lower HbA1c and universal use of RAAS agents and aspirin. 19 The subsequent increased focus on multifactorial risk factor management in diabetes care guidelines has led to a reduction in cardiovascular morbidity and mortality. 20 In fact, the presence of diabetes as a co-morbidity in patients with established cardiovascular disease has been shown to be associated with more comprehensive cardiovascular risk factor management. 21 However, the impact of this approach on cardiomyopathy among those with DM is not clear. Our data, however, would indicate that the improved attention to risk factor management, as tested in this analysis, has also had an impact on preclinical ventricular dysfunction and increased ventricular mass. The optimal target blood pressure in diabetes patients remains unclear but these findings suggest that the presence of diabetes encourages more active control of blood pressure and more success at bringing values within the normal range. In addition, statins were prescribed more frequently in the diabetes cohort, possibly because of a lower threshold to intervene pharmacologically in this group. Better lipid profiles were achieved but in addition we cannot exclude an added non-lipid lowering mediated benefit of statin therapy on ventricular structure and function. 22 Finally, the diabetes cohort were more likely to be treated with RAAS modifying therapy, agents which may be more effective in protecting ventricular structure and function, reducing the development of heart failure and preventing new onset cardiovascular events in asymptomatic patients with diabetes. 23 Dependent on the definitions used, in particular for LVDD, prevalence rates for manifestations of components of Stage B heart failure have been shown to vary significantly among patients with diabetes. 24 We used definitions which reflected significant abnormalities in particular for LVDD and increased LVM. Nonetheless, in excess of 20% of this population still demonstrated significant abnormalites in left ventricular structure or function. These individuals are at risk for the development of HF and other cardiovascular events as shown, for example, by Poulsen et al. 25 showing a prognostic impact of a LAVi measurement of 32 ml/m 2 . In interpreting these data certain features of the study design need to be highlighted. This population has been selected from within the STOP-HF cohort, and thereby excludes patients with a known history of heart failure and established asymptomatic LVSD. In doing so, we may have excluded a higher proportion within the diabetes population with established ALVSD. However, given that routine screening for asymptomatic structural abnormalities of the LV is not a routine practice in diabetes care we feel that our selection process would not have biased the population significantly in this regard.
We cannot exclude that alternate definitions of components parts of Stage B heart failure may have produced modestly different results but would not be likely to change the overall conclusion. The magnitude of Stage B prevalence depends on the cardiac structure and function abnormalities used to select persons for this category and on the criteria chosen to distinguish asymptomatic from symptomatic persons. In this study only echocardiographic abnormalities shown to predict incident HF cases or mortality in the general population were chosen: increased LV mass, significant LVDD and/ or decreased LVEF. Symptoms were determined by specialist assessment prior to Dopplerechocardiography.
This analysis was performed in a routine diabetic population with all the typical attendant comorbidities and risk factors, an appropriate population to study the impact of the proven diabetic insult on the left ventricle on the prevalence of Stage B heart failure. The specific impact of diabetes on the left ventricle would be more precisely studied in a diabetic population without other cardiovascular risk factors, as has already been done in other studies. However, this does not reflect 'real world' care of those with type 2 diabetes where 84.6% of the patients have one or more chronic co-morbid diseases. 26 The diabetes cohort in this population comes predominantly from a shared-care approach to management involving both specialist and primary care teams. The majority of patients would have ready access to important advice from allied healthcare professionals. As a consequence of this care structure, diabetes control was more effective than might be observed in other cohorts, with a mean HbA1c of 54 mmol/mol (7.1%) that corresponds to the level of control achieved in intensive intervention studies. Therefore, findings within this cohort may not be entirely applicable to the wider diabetes population, but nonetheless suggest that maximizing control of risk factors may minimize the potential negative impact of diabetes on ventricular structure and function.
Conclusion
In this large contemporary cohort of patients with cardiovascular risk factors, the presence of diabetes was not associated with an increased prevalence of cardiomyopathy unless adjustment is made for effectiveness of cardiovascular risk factor management. The superior cardiovascular risk factor control and more widespread use of cardioprotective medications in people with diabetes appear to have attenuated the population prevalence of diabetic cardiomyopathy. It will of interest to follow this population longitudinally to ascertain if better risk factor management results in reduced incidence rates of heart failure.
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